Sphingosine 1-phosphate receptor 2 promotes the onset and progression of non-alcoholic fatty liver disease-related hepatocellular carcinoma through the PI3K/AKT/mTOR pathway. Here, S1PR2 is linked to metabolic dysfunction-associated steatotic liver disease.